Amphastar Pharmaceuticals (AMPH)
(Delayed Data from NSDQ)
$47.57 USD
+1.28 (2.77%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $47.56 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$47.57 USD
+1.28 (2.77%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $47.56 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum B VGM
Zacks News
3 Generic Drug Stocks to Watch Amid Macro Headwinds
by Sundeep Ganoria
The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and TEVA.
Is Amphastar Pharmaceuticals (AMPH) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Amphastar Pharmaceuticals (AMPH) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
Amphastar (AMPH) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Amphastar (AMPH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 37.78% and 7.30%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Bausch Health (BHC) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of -30.67% and 0.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year?
by Zacks Equity Research
Here is how Amphastar Pharmaceuticals (AMPH) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.
Zacks.com featured highlights Amphastar, Alpha Metallurgical and Riley Exploration
by Zacks Equity Research
Amphastar, Alpha Metallurgical and Riley Exploration have been highlighted in this Screen of The Week article.
3 Profitable Stocks Worth a Buy Using Net Income Ratio
by Tirthankar Chakraborty
Amphastar Pharmaceuticals (AMPH), Alpha Metallurgical Resources (AMR) and Riley Exploration Permian (REPX) have been selected as the top picks with a high net income ratio.
Strength Seen in Amphastar (AMPH): Can Its 6.4% Jump Turn into More Strength?
by Zacks Equity Research
Amphastar (AMPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Select Medical (SEM) Buys Richmond Post-Acute Care Facility
by Zacks Equity Research
Select Medical (SEM) acquires the Vibra Hospital of Richmond to provide enhanced critical illness recovery care across Virginia.
Here's Why You Should Retain Molina (MOH) in Your Portfolio
by Zacks Equity Research
Molina's (MOH) inorganic growth activities, financial flexibility and cost-cutting initiatives poise it well for growth.
Here's What Makes UnitedHealth Group (UNH) a Lucrative Bet Now
by Zacks Equity Research
UnitedHealth Group (UNH) is well-poised for growth on the back of a growing customer base within its government businesses, efficient telehealth services and solid cash-generating abilities.
Centene (CNC) Expands Evolent Partnership to Boost Quality
by Zacks Equity Research
Centene (CNC) expands the use of Evolent's oncology specialty care to improve cost management.
HCA Healthcare (HCA) Expands in Kansas With a Medical Plaza
by Zacks Equity Research
HCA Midwest, run by HCA Healthcare (HCA), plans to add a two-story medical plaza in Overland Park of $12 million, to be occupied by Family Health Medical Group and Town Plaza Women's Care.
Is Addus HomeCare (ADUS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Addus HomeCare (ADUS) and Amphastar Pharmaceuticals (AMPH) have performed compared to their sector so far this year.
Universal Health (UHS) Up 26% in 6 Months: More Room to Run?
by Zacks Equity Research
Universal Health (UHS) is well-poised for growth on the back of improved patient volumes, acquisitions and robust cash-generating abilities.
Here's Why You Should Retain Acadia (ACHC) in Your Portfolio
by Zacks Equity Research
Diversified revenue base, improving top line, strategic expansion initiatives and joint ventures poise Acadia Healthcare (ACHC) well for growth.
Select Medical (SEM) Forays Into Indiana With Lutheran Health JV
by Zacks Equity Research
Select Medical (SEM) partners with Lutheran Health Network to enhance critical illness recovery and inpatient rehabilitation services in Fort Wayne and neighborhood communities.
Amphastar Pharmaceuticals (AMPH)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
2 Stocks to Buy Now After Powell Flips the Narrative... Again
by Ethan Feller
Expectations for the next FOMC meeting have seen odds of a 50bps rate hike go from extremely unlikely to highly likely
Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Amphastar Pharmaceuticals (AMPH) and Annovis Bio, Inc. (ANVS) have performed compared to their sector so far this year.
3 Generic Drug Stocks to Watch Amid Macro Headwinds
by Sundeep Ganoria
The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and TEVA.
Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 92.11% and 6.80%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Bausch Health (BHC) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of 10.87% and 3.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Bausch (BHC) Stock Jumps 19.3%: Will It Continue to Soar?
by Zacks Equity Research
Bausch (BHC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.